Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Optimizing CAR-T outcomes in DLBCL: possible combination strategies & sequencing of agents

Matthew Ulrickson • 15 Jun 2023
ICML 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma BTK inhibitors CAR-T

Matthew Ulrickson, MD, Banner MD Anderson Cancer Center, Gilbert, AZ, briefly discusses potential combination strategies that may be used with CAR-T therapy to treat patients with diffuse large B-cell lymphoma (DLBCL). Dr Ulrickson comments on the value of bringing CAR-T into earlier lines, and further highlights other agents that may be combined with CAR-T cells to optimize patient outcome. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Matthew Ulrickson

0:57
Zamtocabtagene autoleucel: mechanism of production & potential implications for access
Matthew Ulrickson • 15 Jun 2023
1:09
The changing role of alloSCT in DLBCL in the era of novel agents
Matthew Ulrickson • 15 Jun 2023
1:33
Zamtocabtagene autoleucel for the treatment of patients with R/R DLBCL
Matthew Ulrickson • 15 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals